Before I call the Secretary of State for Health and Social Care, I would like to point out that the British sign language interpretation of the statement will be available to watch on Parliament TV.
I would like to update the House on our work to beat this pandemic and to make sure that the world is prepared for the pandemics of the future.
Tomorrow, we mark six months since the world began vaccinating against covid-19 at Coventry Hospital. In that time, we have vaccinated over 40 million people here in the UK, and 2 billion doses have been delivered across the globe. As of today, 76% of UK adults have been vaccinated at least once, and 52% of adults have had two jabs. The pace of the vaccine roll-out has been extraordinary. This Saturday alone, the team delivered over 675,000 jabs, and I am delighted to be able to tell the House that, from this week, we will start offering vaccinations to people under 30, bringing us ever closer to the goal of offering a vaccine to all adults in the UK by the end of next month.
From tomorrow morning, we will open up vaccination to people aged 25 to 29. Over the remainder of this week, the NHS will send texts to people in those age groups, and, of course, GPs will be inviting people on their list to come forward. I am sure we have all been cheered by the images we have seen of so many eligible young people coming forward and lining up to get the jab, showing that the enthusiasm for the jab is not just the preserve of older generations. The people of this country know what it takes to keep themselves and the people around them safe. The latest estimates indicate that the vaccination programme has averted over 39,000 hospitalisations and over 13,000 deaths. So the vaccination brings us hope, and I am sure the whole House will join me in thanking people for their perseverance and patience as they have waited for their turn.
For all that great progress, there is no room for complacency. The delta variant, first identified in India, has made the race between the virus and the vaccination effort tighter. Although the size of the delta variant’s growth advantage is unclear, the recent best scientific estimate is of an advantage of at least 40% over the previously dominant alpha variant—the so-called Kent variant. The delta variant now makes up the vast majority of all new infections in this country.
3:52 pm
Jonathan Ashworth (Leicester South) (Lab/Co-op)
I am grateful to the Secretary of State for advance sight of his statement. I am also grateful that he has confirmed that the Government’s approach continues to be driven by the data, not by dates. We face some uncertainty, as we often have done throughout the past 15 months, but we do know that the delta variant is now the dominant variant in the UK. We know that 73% of delta cases are in unvaccinated people. We know that one dose offers less protection against this particular variant, and we know that, although hospitalisations are low, an increase in hospitalisations will put significant pressures on the NHS as it tries to deal with the care backlog. We also know, of course, that long covid is significant and debilitating for many people.
I am an optimist and I strongly believe that, ultimately, vaccination is our way through this. Can the Secretary of State go further on vaccination? Is he able to do more to drive up vaccination rates in those areas that have seen the delta variant take off and where uptake remains low, such as Blackburn or my own city of Leicester? Can he narrow the timeframe between the first and second dose, given that we know that one dose is not as protective as we would like? We have seen that Wales will be vaccinating everyone over 18 from next week. Can he tell us when England will follow?
Yesterday, the Secretary of State talked about the outbreaks among schoolchildren and young people. We know that children can transmit the virus and that children can be at particular risk of long covid. In that context, may I ask again why mask wearing is no longer mandatory in secondary schools? I am pleased that he has asked the JCVI to look at vaccination for children; it is something that I have pressed him on a number of times at the Dispatch Box. Can he give us a timeframe on when he expects the JCVI to report on that front?
The Secretary of State talks about the G7. The pandemic has certainly shown that in an interconnected world where climate change and biodiversity loss drive zoonotic spillovers, working internationally to prevent future outbreaks is in our interests. None of us is safe until all of us are safe. That is not a slogan; it is the fact of the situation that we are in. That means working internationally. For a start, it means not cutting international aid, but it also means working globally on our vaccination efforts. He will have seen today that Gordon Brown, Tony Blair and other ex-world leaders have put forward a G7 burden sharing plan that would vaccinate the world. Will the Government support it?
Finally, I welcome what the Secretary of State said about research. Research and science are our way through this pandemic, and our way through to curing so many other diseases and ailments. However, he will know that while we are in this pandemic—while GPs and frontline staff are stretched—patients are unaware that a whole load of GP-held patient data is about to be transferred to NHS Digital.
First, the right hon. Gentleman raised the question of ensuring that we reduce transmission among children. It is true that the increase in case rates has predominantly been among children, especially secondary school-aged children. The testing regime among secondary school-aged children has been enthusiastically taken up by schools across the country. It is very important, as we return from half-term, that that is reinstated in full—that every child is being tested twice a week. It made a big difference in helping to keep schools open. If somebody tested positive at home before they went in, it meant that the whole bubble did not have to go home. It also prevented transmission up to older people, who might be more badly affected. Testing in schools is incredibly important to ensure that we can keep as much education as possible between now and the summer.
The right hon. Gentleman asked about the JCVI advice on children’s vaccination that will be available in a matter of weeks. I know that the JCVI is working hard on it now. I will of course come to the House, Mr Speaker, to explain the proposed approach as soon as we have that formal advice.
Finally, the right hon. Gentleman asked about the use of patient data. I am glad that he said how important he thought research based on data is within the NHS, because it is life-saving. It has been used incredibly powerfully during the pandemic. In fact, one of the reasons why the UK is the place where we discovered some of the life-saving treatments for covid, such as dexamethasone, is the powerful use of data. Just that discovery of dexamethasone, which happened through the use of NHS data, has saved over 1 million lives around the world.
The right hon. Gentleman raised the issue of data, which he said belonged to GPs, being passed to NHS Digital. The truth is that data about his, my or anybody else’s medical condition does not belong to any GP; it belongs, rightly, to the citizen—the patient. That is the approach that we should take. I absolutely agree that it is important to do these things right and properly, but I am also very glad that the vast majority of people are strongly on side for the use of their data to improve lives and save lives. That is the approach that we are going to take in building a modern data platform for the NHS, so that we can ensure that we use this modern asset to improve individuals’ care and to improve research and therefore all our care, while of course preserving the highest standards of safety and privacy, which will be enhanced by a more modern use of data. I am glad that he is on side for the use of data in the NHS, but you have to be on side when that is actually put into practice. It is not just warm words; it is about making it happen.
It is incredibly encouraging that just three out of 12,000 cases of the delta variant were double-jabbed, but is the debate inside Government now about a potential short, temporary extension of the restrictions to allow more people to get both jabs or a more permanent slowing down of the easing of restrictions? That is a massive difference to all our constituents in terms of what may happen following the announcement next week.
Secondly, could the Secretary of State look at one particular group who have been very hard hit over the last year: the parents of disabled children? He will know about my constituent Laura Wilde, who took her nine-year-old daughter, who has cerebral palsy, to Lanzarote for physio that she was unable to get in England and is looking for flexibility in the quarantine rules when she comes back. Can we show more flexibility in exceptional cases such as that?
On the latter point, I am very happy to look at how the case of my right hon. Friend’s constituent Laura Wilde can fit with the exemptions that already apply for travel for medical purposes, along with the testing regime, to ensure that that is done in a safe way. I am happy to talk to colleagues at the Home Office about allowing that to happen.
On my right hon. Friend’s first point, it is reassuring that there is such a clear breakage of the previously inexorable link from cases through to hospitalisations. That is very good news, and it is why we have this race to get everybody vaccinated as soon as possible. If I can address those people in their late 20s who will be able to book a jab from tomorrow and others who might feel that, in their age group, they are unlikely to die of covid, the honest truth is that the best way for us to get our freedoms back and get back to normal is for everybody to come forward and get the jab. It really matters that we all come forward and do this, because that is the safest way out.
On my right hon. Friend’s specific question about our thinking on the 21 June step 4, not before date, the honest answer, which I will give to any question about this, is that it is too early to say. I tried to give a studiously neutral answer on the TV yesterday, which some people interpreted as gung-ho and others interpreted as overly restrictive. That is the nature of uncertainty, I am afraid. It is too early to say. We are looking at all the data, and the road map sets out the approach that we will take, which is that there is step 4 and then there are four distinct pieces of work, which are reports on what should happen after step 4 on social distancing, international travel, certification and the rest. We will assiduously follow the road map process that has been set out with the five-week gap—four weeks to accumulate the data, then taking a decision with a week to go. The Prime Minister will ultimately make those decisions and announce them in a week’s time.
I note that the Secretary of State is still considering ending all social distancing measures on 21 June, but does he not think that that would be dangerous in the face of rising cases of the significantly more infectious delta variant? Would it not be better to adhere to the Government’s mantra of being guided by data and not dates?
While it is welcome that half of adults are fully vaccinated, and Scotland has already started vaccinating those over 18, the Secretary of State must be aware that one dose of the current vaccines only provides 33% protection. Does he accept that that means we cannot rely on single dose vaccination to control this variant without social distancing measures? I and many other MPs repeatedly called for hotel quarantine to be applied to all arrivals in the UK to prevent exactly the situation we now face. He repeatedly claimed that home quarantine was working, but does he not accept that the importation and now dominance of the delta variant shows that is not true? With the current rise in cases of the delta variant threatening the progress made during almost five months of lockdown, does he regret the decision to delay adding India to the red list?
In light of the disruption caused by the shambles of changing Portugal’s classification this week, does the Secretary of State recognise that it has done neither holidaymakers nor the travel industry any favours? Will he now get rid of the traffic light system and tighten border quarantine policy so that we can avoid importing more vaccine-resistant variants and safely open up our domestic economy and society?
The Secretary of State talked today about the UK vaccinating the world, so can he say how many doses the UK has donated to COVAX? Does that mean the Government will support the sharing of intellectual property and technology and the trade-related intellectual property rights—or TRIPS—waiver so as to increase global vaccine production?
There is quite a lot that needs sorting in that. The first thing I would say is that the hon. Lady complains that I acted on Portugal when we saw the data, yet she complains that I did not act on India before we had the data. She cannot have it both ways. She asked me to follow data not dates, but then asked me to prejudge the data by making a decision about 21 June right now. I am a bit confused about that one, too, because I notice that the Scottish Government have themselves been reopening. That is a perfectly reasonable decision for the Scottish Government, but it is a bit rich then for the SNP spokesman to come to this House and have a go at us for deciding to look at the data over the next week, rather than prejudging that decision. It is quite hard to listen and not respond to explain what is actually going on.
The third point I will make is on international vaccination. Absolutely this country has stepped up to the plate. Of the 2 billion doses delivered around the world, half a billion have been the Oxford-AstraZeneca vaccine, which was developed by AstraZeneca and Oxford, with UK taxpayers’ money. It is, as I put it in my statement, a gift to the world. Of course we do not rule out donating excess doses as and when we have them, but only when we have excess doses, and I am sure the hon. Lady will accept that position is agreed not only by the UK Government, but by the devolved Administrations, because we all want to make sure that the people whom we serve get the chance to be vaccinated as soon as possible. That is our approach.
Finally, when it comes to intellectual property, we support intellectual property rights in this country. We could not get drugs to market in the way we manage to without support for intellectual property, because it is often necessary to put billions of pounds into research in order to get the returns over the medium term. What we did, more than a year ago, was agree with Oxford and AstraZeneca that there would be no charge for the intellectual property rights on this vaccine right around the world, and I am delighted that others are starting to take the same approach. Last month, Pfizer announced that in low and lower middle-income countries, it will not charge intellectual property, but we have been on this for more than a year now, so it is a bit rich to hear a lecture from north of the border.
May I ask the Secretary of State about his Department’s role in the latest international travel restrictions? First, what happened to the green watch list, giving more time to prepare for a switch to amber? Did he receive scientific advice that Portugal should be moved to amber, and, if so, will he publish that advice? Has the World Health Organisation recognised the Nepal delta mutation as a variant? Can he confirm that there were just 12 cases of this mutant in Portugal and three times as many in the UK? Ultimately, can he give me a milestone for when we can unlock international travel—perhaps the double-jabbing of over-50s and the clinically extremely vulnerable? Without that milestone, it is difficult to see how we can ever give this industry and workforce hope for their future.
My hon. Friend rightly asks these important questions about the decisions we had to take on Portugal. The truth is that we acted, yes, on the scientific advice: the advice of the joint biosecurity centre, based on the best information we had about this new variant—so-called delta AW, because it is a variant on the delta variant itself. We took that advice.
Restoring international travel in the medium term is an incredibly important goal that we need to work to. It is going to be challenging and hard because of the risk of new variants, and variants popping up in places such as Portugal that otherwise have a relatively low case rate. But the biggest challenge and the reason this is so difficult is that a variant that undermines the vaccine effort would undermine the return to domestic freedom, and that must be protected at all costs.
Thankfully, the delta variant itself, after two doses, gets effectively the same coverage as the old alpha variant or indeed the original variant, so the fact that that is now dominant in the UK does not put our strategy at risk. It makes it more of a challenge of getting from here to there, but that is a challenge for the decision this week and how we handle things in the short term; it does not put the strategy at risk. A variant that undermined the vaccine fundamentally would put us in a much more difficult place as a country, and that is why we are being as cautious as we are.
As the Secretary of State has pointed out himself, data has been key in the pandemic. I agree with him, having previously worked briefly for NHS Digital, that data saves lives. I also agree with him that patient data belongs to the patient, and one of the things I learned during my time working in data is that public trust is key. So why will the Secretary of State not pause this data collection programme, which patients must opt out of by 23 June, to mount a full public information and communication campaign and be explicit about how people’s sensitive data might be used and by whom?
We are explicit about that. I appreciate what the hon. Lady said about the importance of data and data saving lives, and I agree with her about the importance of trust and bringing people with you. In fact, a large majority of those in the NHS are now actively enthusiastic about using data better. I very much hope we can keep it that way, not least because everybody has now seen the importance of using data to manage a crisis. One of the reasons for the vaccine success—why it has been rolled out so effectively—is that the data architecture that underpins the vaccine roll-out is extremely effective, and I pay tribute to the people who built it.
In Harrow, because of the delta variant, we have surge testing in our schools: 13,000 young people have been tested at school and 12,000 relatives at home. This weekend, 3,280 vaccinations took place because we had two new pop-up vaccination centres for 18-year-olds and over. Will my right hon. Friend join me in congratulating the entire team who have made this massive project, so diligently followed, to enable people to be safe in Harrow, but will he also consider having further pop-up clinics for 18-year-olds so that we can get everyone vaccinated as soon as possible?
I pay tribute to the team at Harrow, and especially for the testing expansion. My hon. Friend said that there were 13,000 pupils and 12,000 of their relatives, and that includes me, because one of my children goes to school in the Harrow area. We got our PCR tests at home, we sat around the kitchen table and we all did them together, and I am glad to say they were all negative. This showed me—I felt like a mystery shopper —how effective this surge testing can be in making sure that we tackle these problems. We have seen that surge testing can work. We saw it in south London, where it worked. We have seen it in Bolton, where the case rate has come down. It has been used in Hounslow. It has been used in other specific areas, and I am glad it is now under way in Harrow to try to keep this under control.
I thank the Secretary of State for his statement, as always. He has been clear in the approach that has been taken to the Indian variant, which is currently posing difficulties. I am anxious to understand the level of co-operation and data-sharing with the devolved Assemblies. In particular, I am aware that we are dealing with possible cases in Kilkeel in County Down in Northern Ireland, where 1,000 homes have been visited and 900 tests carried out by a specialised mobile unit. It is clear that the Indian variant problem must have a UK solution presented.
Yes, the hon. Gentleman is absolutely right. We talk about this when the Northern Ireland Health Minister and the Scottish and Welsh Health Secretaries join me on a weekly call. We are acutely aware of the importance of tackling the delta variant, as it is now called, and it is something we work on very closely together across the UK.
Will my right hon. Friend confirm that what he said on “The Andrew Marr Show” was not a change of policy—a sudden retreat from the road map—and that no final decisions have been taken on what happens on 21 June? Can we still hope, in particular, that events involving big gatherings—weddings and all those kinds of things—can start up again, because they are so important both for our economy and jobs and for our quality of life?
20 of 76 shown
Over the past week, we have seen case rates rise, particularly in the north-west of England, but we know also that our surge testing system can help hold this growth. In Bolton, case rates over the past fortnight have been falling. We have expanded the approach taken in Bolton to other areas, and we will roll it out to other areas as necessary. I encourage everybody in those areas to get the tests on offer, no matter where they live. Regular tests can help to keep us all safe, and we know that the test, trace and isolate system has a vital role to play in keeping this all under control.
Of course, the most important tool we have is that vaccination programme. We know that the vaccine is breaking the link between infections, hospitalisations and deaths—a link that was rock-solid back in the autumn. Despite the rise in cases, hospitalisations have been broadly flat. The majority of people in hospital with covid appear not to have had a vaccine at all. I want to update the House on some new information that we have on this. As of 3 June, our data show that of the 12,383 cases of the delta variant, 464 people went on to present at emergency care and 126 were admitted to hospital. Of those 126 people, 83 were unvaccinated, 28 had received one dose and just three had received both doses of vaccine. We should all be reassured by that, because it shows that those vaccinated groups, who previously made up the vast majority of hospitalisations, are now in the minority. So the jabs are working, and we have to keep coming forward to get them. That includes, vitally, that second jab, which we know gives better protection against the delta variant.
The confidence in our jabs comes from the fact that they are working and the knowledge that they are the best way out of the pandemic. No one wants our freedoms to be restricted a single day longer than is necessary. I know the impact that these restrictions have on the things we love, on our businesses and on our mental health. It is still too early to make decisions on step 4. The road map has always been guided by the data and, as before, we need four weeks between steps to see the latest data and a further week, to give notice of our decision. So we will assess the data and announce the outcome a week today, on 14 June.
I know that these restrictions have not been easy. With our vaccine programme moving at such pace, I am confident that one day soon freedom will return. To do this, we must stay vigilant, especially at this time when schoolchildren are returning to classrooms after the half-term break and when we are seeing the highest rises in positive cases among secondary school-aged children. With schools returning today, it is vital that every secondary school-aged child takes a test twice a week to protect them, to help keep schools open and to stop transmission. That is crucial to stop the spread and to protect the education of their peers. While the evidence shows that the impact of covid on children is usually minimal, we also know that there is higher transmissibility among children, so the message to all parents of secondary school-aged children is: please get your child tested twice a week to help keep the pandemic under control and to help on the road to recovery.
The House will also be aware that our independent medicines regulator, the Medicines and Healthcare Products Regulatory Agency, has conducted a review of the clinical trial data for the Pfizer-BioNTech jab. Having already concluded that the vaccine is safe and effective for people over the age of 16, it has also now concluded that the jab is safe and effective for children aged between 12 and 15 years old, with the benefits of vaccination clearly outweighing any risks. I can confirm to the House that I have asked the Joint Committee on Vaccination and Immunisation, the committee that advises us on immunisations, to come forward with clinical advice on vaccinating 12 to 17-year-olds, and we will listen to that clinical advice, just as we have done throughout the pandemic.
People in this country know that vaccines are the way out, but this pandemic will not be over until it is over everywhere. This week, the Prime Minister will host G7 leaders in Cornwall, where he will work to persuade our allies to join the UK in our historic commitment to vaccinate the whole world against covid-19 by the end of 2022. The Oxford-AstraZeneca vaccine has already proved to be a vital tool in this effort, with more than half a billion doses now released for supply around the world and, crucially, delivered at cost. In my view, this approach—providing vaccines at cost—is the best way to vaccinate the world. Developing a vaccine and allowing countries to manufacture it at cost is the greatest gift that this nation could have given the world during the pandemic.
In Oxford, ahead of this week’s G7 leaders summit, I met G7 Health Ministers and guests from some of the world’s largest democracies. Our new clinical trials charter, agreed in Oxford, will help end unnecessary duplication of clinical trials and ensure greater collaboration across borders, resulting in faster access to approve treatments and vaccines. We reached agreement with industry leaders to cut to just 100 days the time that it takes to develop and deploy new diagnostics, therapeutics and vaccines. As a result of what we have agreed in Oxford, there will be people who will live who otherwise might have died, and I can think of no greater outcome than that.
In summary, beating this pandemic is not only an international imperative, but a domestic duty that falls on each one of us. We must keep up the basics, such as hands, face, space and fresh air, get regular tests and, of course, when we get the call, get both jabs, because that is the way that we can stop the spread and get out of this and restore the freedoms that we hold dear safely and together. I commend this statement to the House.
Now, I am not opposed to NHS data being used for public good research, but some of the most sensitive personal data shared with GPs by patients in confidence several years ago—potentially when in a state of vulnerability, such as termination of pregnancy, matters of domestic or sexual abuse and issues of substance misuse or alcohol abuse—is set to be shared with NHS Digital and potentially to be used by commercial interests, and yet hardly anyone knows about it. There are worries about safeguards and patient confidentiality. Given the secrecy, the haste and the difficulties in opting out, will the Secretary of State now consider abandoning this plan, pausing it for now and launching a transparent consultation process with patients and clinicians on how confidential data can best be shared for research purposes?